Maternal HIV-1 DNA load and mother-to-child transmission

AIDS Patient Care and STDs

Volumn 21, Issue 9, 2007, Pages 638-643

  Arvold, Nils D ^a   Ngo Giang Huong, Nicole ^b,c   McIntosh, Kenneth ^a,d   Suraseranivong, Veera ^e   Warachit, Boonyarat ^f   Piyaworawong, Surachai ^g   Changchit, Tikamporn ^h   Lallemant, Marc ^c   Jourdain, Gonzague ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Institute of research for development Thailand   (Thailand)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^f Hatyai Regional Hospital   (Thailand)

^g Mae Chan Hospital   (Thailand)

^h Phan Hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; THAILAND; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; RNA, VIRAL; THAILAND; VIRAL LOAD; ZIDOVUDINE;

EID: 34948831020     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0169     Document Type: Article

References (12)

1. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385-393.
2. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: The French Perinatal Cohort Studies. SEROGEST Cohort Group. J Infect Dis 1997;175:172-175.
3. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
4. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child-transmission. Proc Natl Acad Sci 1995;92:12100-12104.
5. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001;183:539-545.
6. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-552.
7. Montano M, Russell M, Gilbert P, et al. Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis 2003;188:406-413.
8. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343:982-991.
9. Kalish LA, Pitt J, Lew J, et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture: Women and Infants Transmission Study (WITS). J Infect Dis 1997;175:712-715.
10. Burgard M, Chaix ML, Ngo N, et al. Real-time HIV-1 PCR for the diagnosis of infection in newborns of African mothers [Abstract 243]. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, IL: February 2001.
11. Barin F, Lahbabi Y, Buzelay L, et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: An approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses 1996;12:1279-1289.
12. Aleixo LF, Goodenow MM, Sleasman JW. Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. J Pediatr. 1997;130:906-914.